Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Faron Pharmaceuticals Oy
  6. Summary
    FARN   FI4000153309

FARON PHARMACEUTICALS OY

(FARN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/10/2021 09/13/2021 09/14/2021 09/15/2021 09/16/2021 Date
417.5(c) 417.5(c) 417.5(c) 417.5(c) 412.5 Last
2 023 18 993 5 047 4 324 7 960 Volume
0.00% 0.00% 0.00% 0.00% -1.20% Change
More quotes
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 -21,7 M -25,5 M -25,5 M
Net cash position 2021 0,30 M 0,35 M 0,35 M
P/E ratio 2021 -12,2x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -23,9 M -28,1 M -28,1 M
Net Debt 2022 25,9 M 30,4 M 30,4 M
P/E ratio 2022 -9,78x
Yield 2022 -
Capitalization 226 M 266 M 266 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 30
Free-Float 57,3%
More Financials
Company
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic... 
More about the company
All news about FARON PHARMACEUTICALS OY
08/26FARON PHARMACEUTICALS OY : Earnings Flash (FARN.L) FARON PHARMACEUTICALS Reports..
MT
08/26FARON PHARMACEUTICALS OY : Earnings Flash (FARN.L) FARON PHARMACEUTICALS Reports..
MT
08/26FARON PHARMACEUTICALS OY : Earnings Flash (FARN.L) FARON PHARMACEUTICALS OY Repo..
MT
08/26FARON PHARMACEUTICALS OY : Earnings Flash (FARN.L) FARON PHARMACEUTICALS OY Repo..
MT
08/26FARON PHARMACEUTICALS OY : Half-Year Financials, January 1 - June 30 2021
AQ
08/26Faron Pharmaceuticals Oy Reports Earnings Results for the Half Year Ended Jun..
CI
08/25FARON PHARMACEUTICALS OY : Doses First Patient in Phase 2/3 COVID-19 Treatment S..
MT
08/25FARON PHARMACEUTICALS OY : First Patient Dosed in Phase II/III COVID-19 Trial
AQ
08/25Faron Pharmaceuticals Doses First Patient in Phase II/III HIBISCUS Trial of T..
CI
07/28FARON PHARMACEUTICALS OY : Notice of Half-Year Report
AQ
06/22FARON PHARMACEUTICALS OY : Updated corporate presentation
AQ
06/14FARON PHARMACEUTICALS OY : Gets US Patent For Cancer Immunotherapy Bexmarilimab
MT
06/14FARON PHARMACEUTICALS OY : Granted US Patent For Cancer Treatment
MT
06/14FARON PHARMACEUTICALS OY : Bexmarilimab granted key US patent
AQ
06/03FARON PHARMACEUTICALS OY : Bexmarilimab results published in CCR
AQ
More news
News in other languages on FARON PHARMACEUTICALS OY
08/26Earnings Flash (FARN.L) FARON PHARMACEUTICALS annonce un chiffre d'affaires d..
08/26Earnings Flash (FARN.L) FARON PHARMACEUTICALS OY annonce un chiffre d'affaire..
More news
Chart FARON PHARMACEUTICALS OY
Duration : Period :
Faron Pharmaceuticals Oy Technical Analysis Chart | FARN | FI4000153309 | MarketScreener
Technical analysis trends FARON PHARMACEUTICALS OY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 4,89 €
Average target price 6,01 €
Spread / Average Target 22,9%
EPS Revisions
Managers and Directors
Markku Tapani Jalkanen Chief Executive Officer & Executive Director
Toni Haenninen Chief Financial Officer
Frank Murdoch Armstrong Non-Executive Chairman
Matti Karvonen Chief Medical Officer & VP-Drug Development
Jami Mandelin Research Director
Sector and Competitors
1st jan.Capi. (M$)
FARON PHARMACEUTICALS OY60.58%270
GILEAD SCIENCES, INC.23.17%89 973
BIONTECH SE335.78%85 800
REGENERON PHARMACEUTICALS34.96%67 787
WUXI APPTEC CO., LTD.28.41%64 886
VERTEX PHARMACEUTICALS-20.09%48 996